Objective:

To evaluate the effectiveness of CureSight, a digital amblyopia treatment platform, in improving visual and stereo acuity in children with amblyopia linked with anisometropia and/or mild strabismus.

Key Findings:

• Improvements in visual acuity and stereoacuity were noted, including specific metrics from Randot stereotesting and Worth 4 Dot testing.
• CureSight is being prescribed as a first-line therapy by some practitioners.
• The treatment engages the visual system effectively by utilizing streaming content.

Interpretation:

CureSight represents a novel approach to amblyopia treatment, leveraging technology to enhance patient engagement and treatment outcomes.

Limitations:

• Contraindicated for patients with a history of light-induced epilepsy.
• Less recommended for patients with limited attention spans or parental concerns about screen time duration.

Conclusion:

CureSight offers a promising digital solution for amblyopia treatment, with potential for insurance coverage and financial assistance programs.